Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface.

BACKGROUND & AIMS The protease plasmin is an important wound healing factor, but it is not clear how it affects gastrointestinal infection-mediated damage, such as that resulting from Clostridioides difficile. We investigated the role of plasmin in C difficile-associated disease. This bacterium produces a spore form that is required for infection, so we also investigated the effects of plasmin on spores. METHODS C57BL/6J mice expressing the precursor to plasmin, the zymogen human plasminogen (hPLG), or infused with hPLG, were infected with C difficile and disease progression was monitored. Gut tissues were collected and cytokine production and tissue damage were analyzed using proteomic and cytokine arrays. Antibodies that inhibit either hPLG activation or plasmin activity were developed and structurally characterized and their effects were tested in mice. Spores were isolated from infected patients or mice and visualized using super-resolution microscopy; the functional consequences of hPLG binding to spores were determined. RESULTS hPLG localized to the toxin-damaged gut, resulting in immune dysregulation with an increased abundance of cytokines (such as IL1A, IL1B, IL3, IL10, IL12B, MCP1, MP1A, MP1B, GCSF, GMCSF, KC, TIMP-1), tissue degradation, and reduced survival. Administration of antibodies that inhibit plasminogen activation reduced disease severity in mice. C difficile spores bound specifically to hPLG and active plasmin and degraded their surface, facilitating rapid germination. CONCLUSIONS We found that hPLG is recruited to the damaged gut, exacerbating C difficile disease in mice. hPLG binds to C difficile spores, and, upon activation to plasmin, remodels the spore surface, facilitating rapid spore germination. Inhibitors of plasminogen activation might be developed for treatment of C difficile or other infection-mediated gastrointestinal diseases.

[1]  J. Shupe,et al.  Clostridioides difficile infection damages colonic stem cells via TcdB, impairing epithelial repair and recovery from disease , 2020, Proceedings of the National Academy of Sciences.

[2]  D. Morris,et al.  The Use of Tranexamic acid (TXA) for The Management of Haemorrhage In Trauma Patients In The Prehospital Environment: Literature Review and Descriptive Analysis of Principal Themes. , 2020, Shock.

[3]  O. Pilgram,et al.  Fibrinolysis Inhibitors - Potential Drugs for the Treatment and Prevention of Bleeding. , 2020, Journal of medicinal chemistry.

[4]  J. Whisstock,et al.  Structure and Function Characterization of the a1a2 Motifs of Streptococcus pyogenes M Protein in Human Plasminogen Binding. , 2019, Journal of molecular biology.

[5]  J. Whisstock,et al.  Tranexamic acid is an active site inhibitor of urokinase plasminogen activator. , 2019, Blood advances.

[6]  T. Riley,et al.  Diverse bacterial species contribute to antibiotic-associated diarrhoea and gastrointestinal damage. , 2018, The Journal of infection.

[7]  R. König,et al.  Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells , 2018, The Journal of infectious diseases.

[8]  J. Rood,et al.  Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative , 2017, Scientific Reports.

[9]  K. Garey,et al.  Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity , 2017, Clinical and Vaccine Immunology.

[10]  C. Reilly,et al.  Leaky Gut As a Danger Signal for Autoimmune Diseases , 2017, Front. Immunol..

[11]  Christopher M Overall,et al.  Sharpening Host Defenses during Infection: Proteases Cut to the Chase* , 2017, Molecular & Cellular Proteomics.

[12]  G. Ramm,et al.  Atg8 family LC3/GABARAP proteins are crucial for autophagosome–lysosome fusion but not autophagosome formation during PINK1/Parkin mitophagy and starvation , 2016, The Journal of cell biology.

[13]  R. Medcalf,et al.  Plasmin: A Modulator of Immune Function , 2016, Seminars in Thrombosis and Hemostasis.

[14]  J. K. Cheung,et al.  CdtR Regulates TcdA and TcdB Production in Clostridium difficile , 2016, PLoS pathogens.

[15]  Ed J. Kuijper,et al.  Clostridium difficile infection , 2016, Nature Reviews Disease Primers.

[16]  J. González-Miguel,et al.  Plasmin in Parasitic Chronic Infections: Friend or Foe? , 2016, Trends in parasitology.

[17]  Stefan P. Glaser,et al.  Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis , 2016, Nature Microbiology.

[18]  J. Tournier,et al.  Crossing of the epithelial barriers by Bacillus anthracis: the Known and the Unknown , 2015, Front. Microbiol..

[19]  S. Clare,et al.  Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections , 2015, mBio.

[20]  V. Young,et al.  Clostridium difficile and the microbiota. , 2014, The Journal of clinical investigation.

[21]  J. Whisstock,et al.  New insights into the structure and function of the plasminogen/plasmin system. , 2013, Current opinion in structural biology.

[22]  V. Nizet,et al.  Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated Neutrophil Killing , 2013, Journal of Innate Immunity.

[23]  T. Riley,et al.  Novel Molecular Type of Clostridium difficile in Neonatal Pigs, Western Australia , 2013, Emerging infectious diseases.

[24]  N. Seyfried,et al.  Tissue-Type Plasminogen Activator Regulates the Neuronal Uptake of Glucose in the Ischemic Brain , 2012, The Journal of Neuroscience.

[25]  J. Whisstock,et al.  The X-ray crystal structure of full-length human plasminogen. , 2012, Cell reports.

[26]  P. Zipfel,et al.  Plasminogen Is a Complement Inhibitor* , 2012, The Journal of Biological Chemistry.

[27]  J. Rood,et al.  The Anti-Sigma Factor TcdC Modulates Hypervirulence in an Epidemic BI/NAP1/027 Clinical Isolate of Clostridium difficile , 2011, PLoS pathogens.

[28]  T. Riley,et al.  Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia , 2011, The Medical journal of Australia.

[29]  F. Kashanchi,et al.  Bacillus anthracis Interacts with Plasmin(ogen) to Evade C3b-Dependent Innate Immunity , 2011, PloS one.

[30]  A. Sonenshein,et al.  Inhibiting the Initiation of Clostridium difficile Spore Germination using Analogs of Chenodeoxycholic Acid, a Bile Acid , 2010, Journal of bacteriology.

[31]  Julian I. Rood,et al.  Toxin B is essential for virulence of Clostridium difficile , 2009, Nature.

[32]  Joseph A. Sorg,et al.  Laboratory Maintenance of Clostridium difficile , 2009, Current protocols in microbiology.

[33]  B. Wren,et al.  Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. , 2008, Journal of medical microbiology.

[34]  D. Allen,et al.  Binary Toxin Production in Clostridium difficile Is Regulated by CdtR, a LytTR Family Response Regulator , 2007, Journal of bacteriology.

[35]  Alessio Fasano,et al.  Mechanisms of Disease: protease functions in intestinal mucosal pathobiology , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[36]  V. Nizet,et al.  Trigger for group A streptococcal M1T1 invasive disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  Timo K. Korhonen,et al.  Bacterial metastasis: the host plasminogen system in bacterial invasion. , 2005, Trends in microbiology.

[38]  D. Loskutoff,et al.  Plasminogen Has a Broad Extrahepatic Distribution , 2002, Thrombosis and Haemostasis.

[39]  Jordi Félez,et al.  Regulation of plasminogen binding to neutrophils. , 2001, Blood.

[40]  D. Corey,et al.  Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. , 2000, Chemistry & biology.

[41]  J. Johnson,et al.  Molecular characterization of the Clostridium difficile toxin A gene , 1990, Infection and immunity.

[42]  C. Smith,et al.  Transferable tetracycline resistance in Clostridium difficile , 1981, Antimicrobial Agents and Chemotherapy.

[43]  E. Ruitenberg,et al.  The ‘Swiss roll’: a simple technique for histological studies of the rodent intestine , 1981, Laboratory animals.